GLYTR THERAPEUTICS, INC.
Irvine, CA · Biotech · Private
Glycan-dependent T cell Recruiter (GlyTR) immunotherapeutics targeting aberrant N-glycans on solid tumors
glytrtherapeutics.com →- Grants
- $3.6M
- 7 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201820192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · O-Glycan-dependent Immunotherapy for Cancer | $300,614 | |
| Federal grant | Department of Health and Human Services · Phase I · O-Glycan-dependent Immunotherapy for Cancer | $2,084 | |
| Federal grant | Department of Health and Human Services · Phase I · Cancer Immunotherapy Targeting Tn Antigen | $398,178 | |
| Federal grant | Department of Health and Human Services · Phase I · Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy | $400,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy | $908,910 | |
| Federal grant | Department of Health and Human Services · Phase II · Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy | $1,085,460 | |
| Federal grant | Department of Health and Human Services · Phase II · Maximizing GlyTR pan-cancer immunotherapy by enhancing target density | $463,510 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2716 | IMPLICYTE, INC. | — | — |
| 2717 | OnRamp Digital, Inc. | — | $360K |
| 2718 | Mendra | — | — |
| 2719 | GLYTR THERAPEUTICS, INC. | — | — |
| 2720 | SCINTILLATION NANOTECHNOLOGIES INC | — | — |
| 2721 | COMPUTCHEM LLC | — | — |
| 2722 | MIDWEST BIOPROCESSING CENTER LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.